<DOC>
	<DOC>NCT01254188</DOC>
	<brief_summary>This study will further investigate the safety and efficacy of nilotinib in newly diagnosed chronic myeloid leukemia patients in the chronic phase</brief_summary>
	<brief_title>Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<criteria>Patients with chronic myeloid leukemia in the chronic phase diagnosed within 6 months of study entry Treatment with tyrosine kinase inhibitor or other antileukemic agents or treatments (including HSCT) for longer than 2 weeks, with exception of hydroxyurea and/or anagrelide Uncontrolled congestive heart failure or hypertension Myocardial infarction or unstable angina pectoris within past 12 months Known T315I mutations QTcF &gt;450 msec Significant arrhythmias Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Chronic myeloid leukemia,</keyword>
	<keyword>CML,</keyword>
	<keyword>nilotinib,</keyword>
	<keyword>myelogenous,</keyword>
	<keyword>Philadelphia chromosome</keyword>
</DOC>